Resverlogix Corp. J (TSE:RVX)
TSX:RVX
Want to see TSE:RVX full AI Analyst Report?
RVX Stock Chart & Stats
C$0.10
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.10
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.30
Previous CloseN/A
Volume1.00K
Average Volume (3M)37.18K
Market Cap
C$33.20M
Enterprise ValueC$94.61M
Total Cash (Recent Filing)C$107.80K
Total Debt (Recent Filing)C$72.77M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding316,167,270
10 Day Avg. Volume62,041
30 Day Avg. Volume37,183
Financial Highlights & Ratios
PEG Ratio-7.25
Price to Book (P/B)-0.23
Price to Sales (P/S)0.00
P/FCF Ratio-5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Epigenetic PipelineA clear scientific focus on epigenetic mechanisms and BET proteins gives Resverlogix a differentiated research thesis within cardiovascular and metabolic disease. This concentrated R&D strategy supports deeper expertise, clearer go-to-market options, and makes the company a more defined partner candidate for larger biopharma alliances over months.
Lean Operating StructureA very small employee base suggests low fixed overhead and a tightly managed R&D footprint. Over a multi-month horizon this supports capital efficiency, easier prioritization of programs, and the ability to extend runway per financing event compared with larger-cost operations.
Improving Free Cash Flow TrendMeasured improvement in free cash flow indicates incremental progress on expense control or program efficiency. If sustained, this trend reduces near-term external funding pressure and improves the odds that management can advance clinical programs without proportionally larger financings over the next several months.
Bears Say
No Operating RevenueAbsence of revenue means all operations rely on financing or one-time events rather than product sales. This structurally increases execution risk, forces ongoing capital raises to fund R&D, and leaves the firm exposed to financing market cycles and dilution over the next 2–6 months absent a partnering or licensing deal.
Highly Stressed Balance SheetDeeply negative equity and debt exceeding assets materially elevate refinancing and solvency risk. This constrains strategic flexibility, increases the cost and difficulty of raising capital, and could force distressed financings or unfavorable partnership terms if capital is required in the medium term.
Consistent Cash Burn And Funding DependencePersistent negative operating and free cash flows create ongoing reliance on external capital. Over several months this dependency risks dilution, increased borrowing costs, or delayed program timelines if markets tighten, impeding the company's ability to independently advance clinical development.
Resverlogix News
RVX FAQ
What was Resverlogix Corp. J’s price range in the past 12 months?
Resverlogix Corp. J lowest stock price was C$0.04 and its highest was C$0.30 in the past 12 months.
What is Resverlogix Corp. J’s market cap?
Resverlogix Corp. J’s market cap is C$33.20M.
When is Resverlogix Corp. J’s upcoming earnings report date?
Resverlogix Corp. J’s upcoming earnings report date is May 19, 2026 which is in 19 days.
How were Resverlogix Corp. J’s earnings last quarter?
Resverlogix Corp. J released its earnings results on Apr 10, 2026. The company reported -C$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.001.
Is Resverlogix Corp. J overvalued?
According to Wall Street analysts Resverlogix Corp. J’s price is currently Overvalued.
Does Resverlogix Corp. J pay dividends?
Resverlogix Corp. J does not currently pay dividends.
What is Resverlogix Corp. J’s EPS estimate?
Resverlogix Corp. J’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Resverlogix Corp. J have?
Resverlogix Corp. J has 316,167,270 shares outstanding.
What happened to Resverlogix Corp. J’s price movement after its last earnings report?
Resverlogix Corp. J reported an EPS of -C$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Resverlogix Corp. J?
Currently, no hedge funds are holding shares in TSE:RVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Resverlogix Corp. J
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
Technical Analysis
XORTX Therapeutics Inc
―
BriaCell Therapeutics
―
Microbix Biosystms
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―
Options Prices
Currently, No data available
---